BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 12907822)

  • 1. Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies.
    Horstmann S; Kalb P; Koziol J; Gardner H; Wagner S
    Stroke; 2003 Sep; 34(9):2165-70. PubMed ID: 12907822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
    Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR
    Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
    Niebroj-Dobosz I; Janik P; Sokołowska B; Kwiecinski H
    Eur J Neurol; 2010 Feb; 17(2):226-31. PubMed ID: 19796283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A matrix metalloproteinase protein array reveals a strong relation between MMP-9 and MMP-13 with diffusion-weighted image lesion increase in human stroke.
    Rosell A; Alvarez-Sabín J; Arenillas JF; Rovira A; Delgado P; Fernández-Cadenas I; Penalba A; Molina CA; Montaner J
    Stroke; 2005 Jul; 36(7):1415-20. PubMed ID: 15947272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increases in circulating matrix metalloproteinase-9 levels following fibrinolysis for acute pulmonary embolism.
    Mühl D; Ghosh S; Uzuelli JA; Lantos J; Tanus-Santos JE
    Thromb Res; 2010 Jun; 125(6):549-53. PubMed ID: 20307903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia.
    Lorenzl S; Buerger K; Hampel H; Beal MF
    Int Psychogeriatr; 2008 Feb; 20(1):67-76. PubMed ID: 17697439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease.
    Ulrich D; Hrynyschyn K; Pallua N
    Plast Reconstr Surg; 2003 Oct; 112(5):1279-86. PubMed ID: 14504511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic changes of matrix metalloproteinases and their tissue inhibitors in severe sepsis.
    Mühl D; Nagy B; Woth G; Falusi B; Bogár L; Weber G; Lantos J
    J Crit Care; 2011 Dec; 26(6):550-5. PubMed ID: 21530151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Profile of Circulating Matrix Metalloproteinases in Patients Undergoing Lower Limb Endovascular Interventions for Peripheral Arterial Disease.
    Giagtzidis IT; Kadoglou NP; Mantas G; Spathis A; Papazoglou KO; Karakitsos P; Liapis CD; Karkos CD
    Ann Vasc Surg; 2017 Aug; 43():188-196. PubMed ID: 28288884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matrix metalloproteinases and their inhibitors in different acute stroke subtypes.
    Vukasovic I; Tesija-Kuna A; Topic E; Supanc V; Demarin V; Petrovcic M
    Clin Chem Lab Med; 2006; 44(4):428-34. PubMed ID: 16599837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis.
    Klimiuk PA; Sierakowski S; Domyslawska I; Chwiecko J
    J Rheumatol; 2004 Feb; 31(2):238-42. PubMed ID: 14760791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous up-regulation of matrix metalloproteinases 1, 2, 3, 7, 8, 9 and tissue inhibitors of metalloproteinases 1, 4 in serum of patients with chronic obstructive pulmonary disease.
    Navratilova Z; Zatloukal J; Kriegova E; Kolek V; Petrek M
    Respirology; 2012 Aug; 17(6):1006-12. PubMed ID: 22591289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating matrix metalloproteinases and their endogenous inhibitors in patients with erectile dysfunction.
    Muniz JJ; Lacchini R; Belo VA; Nobre YT; Tucci S; Martins AC; Tanus-Santos JE
    Int J Impot Res; 2012; 24(1):38-43. PubMed ID: 21918531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Plasma matrix metalloproteinases MMP-2 and MMP-9 and tissue inhibitors TIMP-1 and TIMP-2 in children treated for acute lymphoblastic leukemia].
    Krawczuk-Rybak M; Kuźmicz M; Mroczko B; Szmitkowski M
    Pol Merkur Lekarski; 2010 Jul; 29(169):14-8. PubMed ID: 20712241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Metalloproteinases MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 levels in children and adolescents with type 1 diabetes].
    Florys B; Głowińska B; Urban M; Peczyńska J
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(3):184-9. PubMed ID: 17020653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased Plasma Matrix Metalloproteinase-9 Levels Contribute to Intracerebral Hemorrhage during Thrombolysis after Concomitant Stroke and Influenza Infection.
    Muhammad S; Planz O; Schwaninger M
    Cerebrovasc Dis Extra; 2016; 6(2):50-9. PubMed ID: 27560521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
    Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
    Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation. The effect of aprotinin and the relation to ischemia/reperfusion injury.
    Kuyvenhoven JP; Molenaar IQ; Verspaget HW; Veldman MG; Palareti G; Legnani C; Moolenburgh SE; Terpstra OT; Lamers CB; van Hoek B; Porte RJ
    Thromb Haemost; 2004 Mar; 91(3):506-13. PubMed ID: 14983226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity.
    Chen CH; Lin KC; Yu DT; Yang C; Huang F; Chen HA; Liang TH; Liao HT; Tsai CY; Wei JC; Chou CT
    Rheumatology (Oxford); 2006 Apr; 45(4):414-20. PubMed ID: 16287916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of hormone replacement therapy type and route of administration on plasma matrix metalloproteinases and their tissue inhibitors in postmenopausal women.
    Lewandowski KC; Komorowski J; Mikhalidis DP; Bienkiewicz M; Tan BK; O'Callaghan CJ; Lewinski A; Prelevic G; Randeva HS
    J Clin Endocrinol Metab; 2006 Aug; 91(8):3123-30. PubMed ID: 16705077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.